• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Cost-Effectiveness Of Combined Treatment With Alteplase (Rt-Pa) And Cerebrolysin In Acute Ischemic Hemispheric Stroke In Austria
Worldwide, stroke is the third most common cause of death in developed countries with declining death rates. In Austria the incidence rate of stroke is 2.1 – 2.3 per thousand annually. Cerebrolysin prevents acute neuronal damage and accelerates recovery after stroke. The purpose of this analysis was to determine costs of stroke for Austria in general and to estimate the cost-effectiveness of Cerebrolysin in combination with alteplase compared to alteplase alone. The analysis should assess health economic advantages in the acute care due to a faster improvement in neurological impairment and for rehabilitation in early po...
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: E Walter, M Bauer, S Ressl Source Type: research

Budget Impact Analysis of The Use of Alteplase In The Treatment of Acute Ischaemic Stroke In Mexico
To estimate the economic impact of the use of alteplase versus best supportive care (BSC) in patients with acute ischemic stroke in Mexico.
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: JL Huicochea-Bartelt, E Palacios, L Zapata, S Herran Tags: CARDIOVASCULAR DISORDERS – Cost Studies Source Type: research

Ischemic stroke patients not receiving life-saving treatment, study finds
(Georgia State University) Ischemic stroke patients who do not receive intravelous (IV) alteplase, a clot-dissolving medication, are significantly less likely to survive, according to researchers at Georgia State University.
Source: EurekAlert! - Medicine and Health - October 12, 2017 Category: International Medicine & Public Health Source Type: news

Budget Impact of Alteplase In Treatment of Acute Ischemic Stroke In Turkey
Cerebrovascular diseases are the sixth cause of total DALYs in Turkey and the Turkish Social Security Institution (SSI) faces a challenge on reimbursement decisions for treatment. Alteplase is a recombinant human tissue plasminogen activator indicated for treatment of acute ischemic stroke (AIS). Clinical trials have proved efficacy in reducing 90-day disability measured by the Modified Rankin Score (mRS) if administered within 4,5 hours of onset of symptoms. The agent is used as an addition to Standard of Care (SoC).
Source: Value in Health - October 1, 2017 Category: International Medicine & Public Health Authors: M Tatar, A Şentürk, E Tetik, L Yıldız, J Cheynel Source Type: research

UCalgary researchers discover critical differences in the clots that cause a stroke
(University of Calgary) There are two main treatments for stroke caused by a clot in a blood vessel in the brain. University of Calgary scientists with the Hotchkiss Brain Institute at the Cumming School of Medicine have discovered that clots have different compositions and depending on where they are located in the brain, administering the clot-busting drug, Alteplase (also known as tPA), can be almost as effective as thrombectomy given sufficient time.
Source: EurekAlert! - Medicine and Health - September 11, 2018 Category: International Medicine & Public Health Source Type: news

Cost-Effectiveness of Magnetic Resonance Imaging-Guided Thrombolysis for Patients With Stroke With Unknown Time of Onset
Patients waking up with stroke symptoms are often excluded from intravenous thrombolysis with alteplase (IV-tpa). The WAKE-UP trial, a European multicenter randomized controlled trial, proved the clinical effectiveness of magnetic resonance imaging-guided IV-tpa for these patients. This analysis aimed to assess the cost-effectiveness of the intervention compared to placebo.
Source: Value in Health - August 2, 2021 Category: International Medicine & Public Health Authors: Louisa-Kristin Muntendorf, Alexander Konnopka, Hans-Helmut K önig, Florent Boutitie, Martin Ebinger, Matthias Endres, Jochen B. Fiebach, Vincent Thijs, Robin Lemmens, Keith W. Muir, Norbert Nighoghossian, Salvador Pedraza, Claus Z. Simonsen, Christian Ge Tags: Economic Evaluation Source Type: research

EE477 Budgetary Impact Analysis of Alteplase - Recombinant Tissue Plasminogen Activator (RTPA) - As a Thrombolytic Treatment for Acute Ischemic Stroke in Colombia
to evaluate the potential impact on costs and health outcomes of increasing the proportion of patients with acute ischemic stroke (AIS) who are thrombolyzed with alteplase in Colombia and of reducing the time to initiate treatment.
Source: Value in Health - June 26, 2022 Category: International Medicine & Public Health Authors: P Lasalvia Source Type: research

EE568 Tenecteplase or Alteplase for Acute Ischemic Stroke? A Cost-Effectiveness Analysis
Alteplase is widely used as intravenous thrombolytic medication in acute ischemic stroke (AIS). However, tenecteplase, a genetically modified form of alteplase, has recently been shown to result in higher recanalization rates, improved functional outcome and a similar safety profile in AIS patients with large vessel occlusion (LVO) compared to alteplase. Accordingly, this study aims to evaluate the cost-effectiveness of 0.25mg/kg tenecteplase versus 0.9mg/kg alteplase for thrombolysis in AIS patients due to LVO from the Dutch healthcare payer perspective.
Source: Value in Health - December 1, 2022 Category: International Medicine & Public Health Authors: C Nguyen, MMH Lahr, DJ Van der Zee, H Van Voorst, YBWEM Roos, M Uyttenboogaart, E Buskens Source Type: research